Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 15 studies | 29% ± 9% | |
lung | 12 studies | 27% ± 12% | |
kidney | 7 studies | 21% ± 5% | |
intestine | 7 studies | 24% ± 11% | |
brain | 6 studies | 30% ± 24% | |
lymph node | 5 studies | 22% ± 2% | |
uterus | 4 studies | 28% ± 13% | |
breast | 4 studies | 21% ± 2% | |
placenta | 3 studies | 25% ± 11% | |
eye | 3 studies | 23% ± 5% | |
thymus | 3 studies | 44% ± 19% | |
liver | 3 studies | 35% ± 23% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1027.39 | 1445 / 1445 | 100% | 50.14 | 183 / 183 |
intestine | 100% | 1083.40 | 966 / 966 | 100% | 76.02 | 527 / 527 |
liver | 100% | 779.37 | 226 / 226 | 100% | 54.29 | 406 / 406 |
lung | 100% | 1037.22 | 578 / 578 | 100% | 71.19 | 1155 / 1155 |
ovary | 100% | 1183.48 | 180 / 180 | 100% | 93.10 | 430 / 430 |
skin | 100% | 1201.15 | 1809 / 1809 | 100% | 63.16 | 472 / 472 |
stomach | 100% | 807.20 | 359 / 359 | 100% | 69.52 | 286 / 286 |
uterus | 100% | 1261.08 | 170 / 170 | 100% | 126.06 | 459 / 459 |
thymus | 100% | 1372.82 | 653 / 653 | 100% | 84.73 | 604 / 605 |
prostate | 100% | 899.03 | 245 / 245 | 100% | 54.13 | 501 / 502 |
breast | 100% | 1204.95 | 459 / 459 | 100% | 73.78 | 1114 / 1118 |
bladder | 100% | 1071.76 | 21 / 21 | 100% | 92.87 | 502 / 504 |
kidney | 100% | 1052.30 | 89 / 89 | 99% | 46.23 | 894 / 901 |
brain | 99% | 670.68 | 2623 / 2642 | 100% | 47.67 | 704 / 705 |
pancreas | 100% | 554.35 | 327 / 328 | 99% | 63.44 | 177 / 178 |
adrenal gland | 100% | 1066.27 | 258 / 258 | 99% | 45.04 | 227 / 230 |
adipose | 100% | 1161.51 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1041.51 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 116.19 | 29 / 29 |
spleen | 100% | 1229.90 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 98.45 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 60.88 | 1 / 1 |
muscle | 99% | 659.01 | 798 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 643.73 | 852 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 47.26 | 78 / 80 |
peripheral blood | 94% | 859.78 | 869 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0050684 | Biological process | regulation of mRNA processing |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0006406 | Biological process | mRNA export from nucleus |
GO_0008380 | Biological process | RNA splicing |
GO_2000622 | Biological process | regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay |
GO_0000184 | Biological process | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay |
GO_0000381 | Biological process | regulation of alternative mRNA splicing, via spliceosome |
GO_0006417 | Biological process | regulation of translation |
GO_0016607 | Cellular component | nuclear speck |
GO_0035145 | Cellular component | exon-exon junction complex |
GO_0071013 | Cellular component | catalytic step 2 spliceosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_1990501 | Cellular component | exon-exon junction subcomplex mago-y14 |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | MAGOH |
Protein name | Protein mago nashi homolog |
Synonyms | MAGOHA |
Description | FUNCTION: Required for pre-mRNA splicing as component of the spliceosome . Plays a redundant role with MAGOHB as core component of the exon junction complex (EJC) and in the nonsense-mediated decay (NMD) pathway . The EJC is a dynamic structure consisting of core proteins and several peripheral nuclear and cytoplasmic associated factors that join the complex only transiently either during EJC assembly or during subsequent mRNA metabolism. The EJC marks the position of the exon-exon junction in the mature mRNA for the gene expression machinery and the core components remain bound to spliced mRNAs throughout all stages of mRNA metabolism thereby influencing downstream processes including nuclear mRNA export, subcellular mRNA localization, translation efficiency and nonsense-mediated mRNA decay (NMD). The MAGOH-RBM8A heterodimer inhibits the ATPase activity of EIF4A3, thereby trapping the ATP-bound EJC core onto spliced mRNA in a stable conformation. The MAGOH-RBM8A heterodimer interacts with the EJC key regulator PYM1 leading to EJC disassembly in the cytoplasm and translation enhancement of EJC-bearing spliced mRNAs by recruiting them to the ribosomal 48S preinitiation complex. Involved in the splicing modulation of BCL2L1/Bcl-X (and probably other apoptotic genes); specifically inhibits formation of proapoptotic isoforms such as Bcl-X(S); the function is different from the established EJC assembly. . |
Accessions | P61326 ENST00000371466.4 [P61326-2] ENST00000371470.8 [P61326-1] |